VIENNA, Va., June 4 /PRNewswire-FirstCall/ -- In response to numerous shareholder questions, CEL-SCI CORPORATION (Amex: CVM) is providing an update on the construction of its manufacturing facility near Baltimore, Maryland. The facility, when fully built out, will comprise 73,000 square feet and will be used to manufacture Multikine(R), the Company's lead cancer product. This dedicated facility will produce the Multikine that will be used for CEL-SCI's pivotal Phase III clinical trial for first-line therapy of previously untreated head and neck cancer patients, and subsequently for sale following approval of the drug.
Upon completion of the first phase of the build out (28,000 square feet) in the 2008 third quarter, the facility will be capable of supporting approximately $600 million of annual commercial sales of Multikine. The facility build out is currently about 70% complete. The facility is being developed for CEL-SCI by BioRealty, Inc. (http://www.biorealty.com) and the design builder is BE&K, Inc. (http://www.bek.com/index.asp). Pictures of the manufacturing facility, located close to Baltimore, MD, can be accessed on CEL-SCI's website at http://www.cel-sci.com under "Special Highlights", "Pictures of Manufacturing Facility".
"CEL-SCI has been advised by BE&K that the manufacturing facility is on
target to be completed on schedule," said Geert Kersten, CEL-SCI's Chief
Executive Officer. "The facility will provide CEL-SCI with tight control
over the Multikine manufacturing process, eliminating key risks to the
successful completion of the pivotal Phase III trial
|SOURCE CEL-SCI CORPORATION|
Copyright©2008 PR Newswire.
All rights reserved